{"nctId":"NCT00458393","briefTitle":"Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men","startDateStruct":{"date":"2007-06"},"conditions":["HIV Infections"],"count":2499,"armGroups":[{"label":"TDF/FTC","type":"EXPERIMENTAL","interventionNames":["Drug: daily TDF/FTC"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"daily TDF/FTC","otherNames":["truvada"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male sex (at birth)\n* HIV uninfected\n* Age having reached the local age of consent\n* High risk for HIV infection including any of the following: 1) No condom use during anal intercourse with a male HIV-positive partner or a male partner of unknown HIV status during the last 6 months; (2) anal intercourse with more than 3 male sex partners during the last 6 months; (3) exchange of money, gifts, shelter, or drugs for anal sex with a male partner during the last 6 months; (4) sex with a male partner and STI diagnosis during the last 6 months or at screening, or (5) sexual partner of an HIV-infected man with whom condoms are not consistently used in the last 6 months.\n* Able to provide a street address of residence for themselves and one personal contact who would know their whereabouts during the study period\n* Healthy enough to work, as indicated by score of 80 or greater on the Karnofsky scale\n* Certain laboratory values\n* A urine dipstick with a negative or trace result for both glucose and protein within 28 days of enrollment.\n* Ability to understand and local language for which an informed consent form has been approved by a local IRB and registered with the study sponsor.\n\nInclusion Criteria for Open-Label Extension:\n\n* Participated in a randomized, placebo-controlled, PrEP trail\n* Has been unblinded\n* Has provided informed consent\n\nExclusion Criteria:\n\n* Previously diagnosed active and serious infections, including tuberculosis infection, osteomyelitis, or infections requiring parenteral antibiotic therapy\n* Active clinically significant medical problems including heart disease (e.g., symptoms of ischemia, congestive heart failure, arrhythmia), lung disease (steroid-dependent chronic obstructive pulmonary disease), diabetes requiring hypoglycemic medication, or previously diagnosed cancer expected to require further treatment\n* Acute HBV infection at the screening visit or presence of treatment indications for hepatitis B based on local practice standards; or clinical signs of hepatic cirrhosis\n* History of pathological bone fractures not related to trauma\n* Receiving ongoing therapy with certain HIV/AIDS-related medications or other medications as determined by the investigator\n* Definitely or possibly received an anti-HIV vaccine while participating in a blinded clinical trial\n* Current alcohol or drug use that, in the opinion of the investigator, may interfere with the study\n* Current participation in a clinical trial or cohort study other than sub-studies of this protocol\n* Any condition at enrollment that, in the opinion of the investigator, would make participation in the study unsafe or would interfere with the study\n* Sites may utilize additional criteria that restrict enrollment to a subset of people who meet the protocol-defined enrollment criteria.\n\nExclusion Criteria for Open-Label Extension:\n\n\\- Site leadership believes participant will have difficulty completing requirements","healthyVolunteers":true,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HIV Seroconversion","description":"Confirmed HIV infection","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"PRIMARY","title":"Grade 1 or Higher Creatinine Toxicity","description":"Creatinine which reach grade 1 (mild, 1.1 to 1.3 local upper limit of normal) or higher by the US Division of AIDS grading table (version 1) or a 50% increase in creatinine from the baseline value. The DAIDS table can be found at https://rsc.tech-res.com/docs/default-source/safety/table\\_for\\_grading\\_severity\\_of\\_adult\\_pediatric\\_adverse\\_events.pdf","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"PRIMARY","title":"Grade 3 or Higher Phosphorous Toxicity","description":"Grade 3 or higher phosphorous toxicity (hypophosphatemia) by the Division of AIDS Grading Table (severe, level at or below 1.9 mg/dL)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"PRIMARY","title":"Grade 2, 3, or 4 Laboratory Adverse Events","description":"Number of participants with at least one Grade 2, 3, or 4 laboratory adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table\\_for\\_grading\\_severity\\_of\\_adult\\_pediatric\\_adverse\\_events.pdf","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]},{"type":"PRIMARY","title":"Grade 2, 3, or 4 Clinical Adverse Events","description":"Number of participants with at least 1 Grade 2, 3, or 4 clinical adverse events (moderate, severe of life threatening based one the US Division of AIDS Grading of adverse events, version 1.0). The table can be found at https://rsc.tech-res.com/docs/default-source/safety/table\\_for\\_grading\\_severity\\_of\\_adult\\_pediatric\\_adverse\\_events.pdf","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"162","spread":null}]}]}]},{"type":"SECONDARY","title":"Hepatitis Flares Among Hepatitis B Virus (HBV) Infected Persons During and After Chemoprophylaxis","description":"A hepatic flare is defined as an increase in alanine transaminase or aspartate transaminase to \\>5 fold upper limit of normal at any visit, or an increase to \\>2.5 fold upper limit of normal for 3 months, within 24 weeks of permanently stopping study drug.\n\nMore details in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752387/","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Bone Mineral Density","description":"% Change from baseline in bone mineral density (100 \\* \\[(value at 24 weeks- value at baseline)/ (value at baseline)\\]) in in hip and L1-L4 spine by dual-energy x-ray absorptiometry","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.59","spread":"0.21"},{"groupId":"OG001","value":"0.32","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"0.16"},{"groupId":"OG001","value":"0.29","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Body Fat","description":"Percentage Change (100 \\* \\[(value at 24 weeks- value at baseline)/ (value at baseline)\\]) in Body Fat from Baseline by dual-energy x-ray absorptiometry","paramType":"MEDIAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.0"},{"groupId":"OG001","value":"3.8","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Fasting Triglycerides","description":"Percentage Change (Percentage Change (100 \\* \\[(value at 24 weeks- value at baseline)/ (value at baseline)\\]) in Triglycerides from Baseline from a fasting sample.","paramType":"MEDIAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"3.3"},{"groupId":"OG001","value":"0.0","spread":"3.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Cholesterol","description":"Percent change (100 \\* \\[(value at 24 weeks- value at baseline)/ (value at baseline)\\]) in fasting total cholesterol from baseline","paramType":"MEDIAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"1.2"},{"groupId":"OG001","value":"-1.1","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Viral Load Among HIV Infected Participants","description":"HIV-RNA in log10 units among HIV infected participants at the time closest to HIV detection","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"0.11"},{"groupId":"OG001","value":"5.1","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Among HIV Infected Participants Drug Resistance","description":"Genotypic resistance by clinical assays among the seroconverters from baseline to the end of the study treatment period","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"CD4 Count Among HIV Infected Participants","description":"CD4 cell count for HIV infected participants during the trial","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"495","spread":null},{"groupId":"OG001","value":"502","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Missed Doses by Pill Count","description":"Estimated proportion of missed doses by pill count (assuming pills taken in unreturned bottles)","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":null},{"groupId":"OG001","value":"0.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Missed Doses by Estimate During CASI Interview","description":"Percentage of missed doses by estimate during computer assisted structured interview","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":"0.5"},{"groupId":"OG001","value":"91.2","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Number of Condomless Sexual Partners With HIV Positive or Unknown Status","description":"Participants self-report of the number of sexual partners with HIV positive or unknown status in the previous 12 weeks with whom they had condomless anal sex","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Number of Sexual Partners","description":"Self-reported total number of sexual partners in the previous 12 weeks.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Condomless Receptive Anal Intercourse in the Previous 12 Weeks With Any Partners Regardless of Status.","description":"Self-reported condomless receptive anal intercourse in the previous 12 weeks with any partners regardless of status.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"332","spread":null},{"groupId":"OG001","value":"348","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Confirmed Syphilis During Follow-Up","description":"Number of participants who have at least 1 confirmed syphilis infection during the study","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"132","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of HSV-2 During the Follow-up Period","description":"Incidence of HSV-2 during the follow-up period among those HIV-2 negative at baseline","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Diagnosis of Gonorrhea During the Follow-up Period","description":"Diagnosis of gonorrhea during the follow-up period by PCR","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":92,"n":1226},"commonTop":["PHARYNGITIS","PARASITIC INFECTION INTESTINAL","ALANINE AMINOTRANSFERASE INCREASED","BILIRUBIN INCREASE","DIARRHOEA"]}}}